-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Beta Bionics, Raises Price Target to $19

Benzinga·07/15/2026 16:46:55
Listen to the news
Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $17 to $19.